Expected Normal Ketone Values After Very Low and Bariatric Surgery

Sponsor
St Vincent's Hospital Melbourne (Other)
Overall Status
Completed
CT.gov ID
NCT05442918
Collaborator
(none)
55
1
10.9
5

Study Details

Study Description

Brief Summary

The investigators propose a multicenter prospective study in patients undergoing either an elective bariatric procedure or an elective benign procedure, including laparoscopic/open cholecystectomy, laparoscopic/open hiatus hernia repair, laparoscopic/open inguinal hernia repair, laparoscopic/open umbilical hernia repair or laparoscopic ventral wall hernia repair. Perioperative blood ketone and venous blood gas levels will be measured pre-surgery, post-surgery and on post-operative days until discharge.

Our primary research objective is to clarify the expected perioperative ketone and blood gas levels in elective bariatric patients who have been on a VLCD and fasting for surgery, compared to elective surgical patients who have only been fasting prior to surgery.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Bariatric surgery is fast becoming a mainstream option for achieving long-term weight loss in the morbidly obese population due to the paucity of other effective alternatives. It is indicated in those with a Body Mass Index (BMI) >40, or those with an obesity-related comorbidity with a BMI >35. One of the most common of these comorbidities is Type 2 Diabetes Mellitus (T2DM).

    In the weeks preceding bariatric surgery, it is routine for patients to be placed on a very low calorie diet (VLCD). The aim is to reduce abdominal wall thickness, visceral adiposity and hepatomegaly. Overall, this contributes to reduced technical difficulties at operation.

    VLCD achieve rapid weight loss in the short term by inducing ketosis. This is achieved by reducing the consumption of carbohydrate and fat, while increasing protein intake. The depletion of caloric intake leads to decreased glucose stores. This then leads to a metabolic shift towards production of ketone bodies, which are produced by the liver via the oxidation of fatty acids. Ketones are then transported to tissue to take over the role of glucose as the main energy source for the central nervous system. The objective is to reduce fat mass without causing excess loss of muscle mass.

    Overall the VLCD regime, via the induction of ketosis, is very successful in weight reduction. However this mechanism of action, and the production of ketone bodies, is now being questioned in those prescribed a new class of glucose lowering medication used to treat T2DM.

    Sodium-glucose co-transporter-2 (SGLT2) inhibitors, also called gliflozins, are medications that reduce absorption of glucose in the kidney thus increasing excretion via urine. Phase 3 trials have shown them to be safe for treatment of T2DM however; however concern has been raised about development of a euglycaemic diabetic ketoacidosis. It is thought to occur when stress hormones lead to increased ketosis in patients taking SGLT2 inhibitors, which appear to alter insulin production. This situation can occur in the perioperative period if the SGLT2 inhibitors have not been correctly withheld pre-operatively.

    Current guidelines from the Australian and New Zealand College of Anaesthetists recommend the cessation of SLGT2 inhibitors 3 days prior to surgery. If this has not occurred, they state blood ketones should be tested. If the blood ketones are >0.6, it is a strong recommendation to postpone non-urgent surgery. Ketone and base excess levels are then used to monitor patients in the perioperative period.

    The confounding factor in these patients now presents itself- what are the expected blood ketone levels in bariatric patients who have been on two week of pre-operative VLCD and are fasting for surgery?

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    55 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Expected Normal Ketone Values After Very Low and Bariatric Surgery
    Actual Study Start Date :
    Jan 15, 2020
    Actual Primary Completion Date :
    Dec 11, 2020
    Actual Study Completion Date :
    Dec 12, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    General Surgery

    All patients undergoing either elective laparoscopic/open cholecystectomy, laparoscopic/open hiatus hernia repair, laparoscopic/open inguinal hernia repair, laparoscopic/open umbilical hernia repair or laparoscopic ventral wall hernia repair.

    Bariatric Surgery

    Participants undergoing elective bariatric surgery (laparoscopic sleeve gastrectomy or roux-en-y gastric bypass). Those in the bariatric arm must have been on a VLCD pre operatively

    Outcome Measures

    Primary Outcome Measures

    1. Blood ketone [Immediately prior to surgery, immediately post-surgery, daily until discharge until up to 1 week]

      blood ketone levels

    2. Venous blood gas levels [Immediately prior to surgery, immediately post-surgery, daily until discharge until up to 1 week]

      Primary outcome measures are blood ketone, and venous blood gas levels.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    General surgery group, undergoing the following elective surgeries:
    • laparoscopic/open cholecystectomy

    • laparoscopic/open hiatus hernia repair

    • laparoscopic/open inguinal hernia repair

    • laparoscopic/open umbilical hernia repair

    • laparoscopic ventral wall hernia repair

    Bariatric surgery group, undergoing the following elective surgeries and a very low calorie diet before surgery:

    • laparoscopic sleeve gastrectomy

    • laparoscopic roux-en-y gastric bypass

    Exclusion Criteria:
    • currently on SLGT2 inhibitor

    • non English speaking

    • procedure abandoned

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St Vincent's Hospital Melbourne Fitzroy Victoria Australia 3065

    Sponsors and Collaborators

    • St Vincent's Hospital Melbourne

    Investigators

    • Principal Investigator: Michael Hii, FRACS, St Vincent's Hospital Melbourne

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Hii, Doctor, St Vincent's Hospital Melbourne
    ClinicalTrials.gov Identifier:
    NCT05442918
    Other Study ID Numbers:
    • StVincentsMelbourne
    First Posted:
    Jul 5, 2022
    Last Update Posted:
    Jul 5, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 5, 2022